Artelo Biosciences Executes 1-for-9 Reverse Split to Regain Nasdaq Compliance
ARTL is trading near its 52-week low of $0.66 (0.3% below the low) on light trading volume (0.3× avg).
Summary
Artelo Biosciences announced a 1-for-9 reverse stock split effective August 28, 2026, cutting outstanding shares from ~4.93M to ~547,774 to boost the share price and maintain Nasdaq listing.
Key Events · Corporate Governance and Compliance · ARTL
-
1-for-9 Reverse Split Executed
Effective August 28, 2026 at 5:00 p.m. ET, each nine pre-split shares combine into one new share, reducing outstanding shares from 4,929,966 to approximately 547,774.
-
Authorized Shares Reduced Proportionally
Authorized common stock drops from 500,000,000 to 55,555,556 shares, maintaining the same ratio and preserving the board's ability to issue shares without further stockholder approval.
-
Nasdaq Compliance Pressure
The reverse split is intended to raise the per-share price — currently $0.658, near the 52-week low of $0.66 — to improve marketability and liquidity and support Nasdaq listing requirements.
-
Financial Distress Backdrop
The split follows a $2.4 million Q2 net loss, going-concern doubts, and only $4.2 million in cash as of the August 12, 2026 10-Q, underscoring the company's fragile position.
Analysis · ARTL · Life Sciences
Artelo Biosciences is executing a 1-for-9 reverse stock split effective August 28, 2026, reducing outstanding shares from roughly 4.93 million to about 547,774. The move is aimed at lifting the share price — currently $0.658, just above the 52-week low of $0.66 — to improve marketability and liquidity. The company has been under pressure: a $2.4 million Q2 net loss, going-concern doubts, and only $4.2 million in cash as of the last 10-Q. The reverse split is a survival maneuver to maintain Nasdaq listing requirements, but it does not change the underlying financial distress. Shareholders keep the same pro-rata ownership, but the higher per-share price can mask the company's small size and may invite renewed selling pressure.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.66 to $28.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.